New Standard Therapy for Heart Failure with Reduced Ejection Fraction

New Standard Therapy for Heart Failure with Reduced Ejection Fraction - When and How to Introduce SGLT2 Inhibitors Guest: Margaret M. Redfield, M.D. Host: Malcolm R. Bell, M.D. A new class of agents with powerful effects on cardiovascular outcomes has quickly amassed a compelling body of evidence for its use: sodium-glucose cotransporter-2 (SGLT2) inhibitors. Joining us today to discuss the use of SGLT2 inhibitors for the treatment of patients with heart failure with reduced ejection fraction (HFrEF) is Margaret M. Redfield, M.D., a cardiologist and heart failure specialist at Mayo Clinic in Rochester, Minnesota. Specific topics discussed: Evidence supporting the use of SGLT2 inhibitors in patients with HFrEF Treatment impact on patients with heart and renal failure Patients who are ineligible for use of SGLT2 inhibitors How to select patients and begin treatment in the outpatient setting, including titration requirements Collaboration with specialists managing care for patients with diabetes Inpatient treatment Overcoming hesitation among cardiologists in prescribing SGLT2 inhibitors Considerations for the treatment of patients who present with diabetic ketoacidosis Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV. NEW Cardiovascular Education App:The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.